Trial Profile
Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2017
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 14 Sep 2017 Status changed from recruiting to discontinued.
- 19 Jul 2016 New trial record